Home / Business / Associated Banc Corp holds a position of $ 5.13 million at Gilead Sciences, Inc. (GILD)

Associated Banc Corp holds a position of $ 5.13 million at Gilead Sciences, Inc. (GILD)



  Gilead Sciences logo "title =" Gilead Sciences logo "class =" companylogo "/> Associated Banc Corp reduced its stake in Gilead Sciences, Inc. (NASDAQ: GILD) shares by 35.2% during the second quarter , according to its most recent 13F filing with the SEC, the company owned 72,453 shares of the biopharmaceutical company after selling 39,436 shares during the period.The Associated Banc Corp holdings in Gilead Sciences were worth $ 5,128,000 at the end of the most recent quarter.</p><p> Other large investors also recently added or reduced their shareholdings Pioneer Investment Management Inc. increased its position in Gilead Sciences by 84.0% in the second quarter Pioneer Investment Management Inc. now owns 3,493,1<div class=

48 shares of the biopharmaceutical company with a value of $ 247,245,000 after acquiring 1,595,085 additional shares during the last quarter. Berman Group LLC increased its position in Gilead Sciences shares by 90.9% during the 2nd. arter. Neuberger Berman Group LLC now owns 2,583,196 shares of the biopharmaceutical company's stock for $ 182,839,000 after buying 1,229,916 additional shares in the last quarter. Harbor Capital Advisors LLC increased its position in Gilead Sciences shares by 6,595.9% during the second quarter. Harbor Capital Advisors LLC now holds 1,221,804 shares of the biopharmaceutical company with a value of $ 17,262,000 after buying 1,203,557 additional shares in the last quarter. Principal Financial Group Inc. boosted its position in Gilead Sciences by 41.2% during the second quarter. Principal Financial Group Inc. now owns 3,909,105 shares of the biopharmaceutical company's stock valued at $ 276,687,000 after buying 1,140,112 additional shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. increased its position in Gilead Sciences by 75.0% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company valued at $ 173,148,000 after buying 1,092,206 additional shares in the last quarter. Institutional investors own 76.23% of the company's shares.

In related news, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences in a transaction that occurred on Thursday, September 7. The stock was sold at an average price of $ 85.00, for a total transaction of $ 4,404,700.00. After the transaction, the CFO now holds 43.352 shares in the company, valued at $ 3,684,920. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In addition, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences in a transaction that took place on Monday, October 2. The stock was sold at an average price of $ 82.65, for a total value of $ 2,066,250.00. The disclosure of this sale can be found here. In the last quarter, the initiates have sold 546,819 shares of the company's stock for a value of $ 41,808,839. 1.30% of the shares are currently owned by company experts.

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) remained stable at $$ 73.29 during business hours on Wednesday. The company had a trading volume of 6,077,088 shares, compared to its average volume of 9,215,701. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a fast ratio of 3.56. The stock has a market capitalization of $ 95,475.20, a price-earnings ratio of 7.63, a price-profit-growth ratio of -1.22 and a beta of 1.13. Gilead Sciences, Inc. has a minimum of 52 weeks of $ 63.76 and a maximum of 52 weeks of $ 86.27.

Gilead Sciences (NASDAQ: GILD) last issued its quarterly earnings results on Thursday, October 26. The biopharmaceutical company reported $ 2.27 of earnings per share (EPS) for the quarter, beating Zacks' consensus estimate of $ 2.13 for $ 0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenues of $ 6.51 billion for the quarter, compared to analysts' estimates of $ 6.40 billion. During the same period of the previous year, the company recorded earnings per share of $ 2.75. The company's income decreased 13.2% year-on-year. Research analysts predict that Gilead Sciences, Inc. will record 8.53 earnings per share for the current year.

The business also recently revealed a quarterly dividend, which will be paid on Thursday, December 28. Investors registered on Friday, December 15 will receive a dividend of $ 0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a dividend of $ 2.08 annualized and a yield of 2.84%. The payment index of Gilead Sciences is 23.69%.

Several research firms have commented on GILD. BidaskClub reduced Gilead Sciences from a "buy" rating to a "suspense" rating in a research note on Wednesday, August 9. Mizuho reiterated a "buy" rating on Gilead Sciences shares in a research note on Friday, September 29. Maxim Group reiterated a "suspension" rating on Gilead Sciences shares in a research note on Thursday, October 19. Berenberg Bank restated a "buy" rating and issued a price target of $ 86.00 (up to $ 79.00) on Gilead Sciences shares in a research note on Sunday, August 20. Finally, Cowen reiterated a "superior performance" rating and issued a price target of $ 90.00 on shares of Gilead Sciences in a research note on Thursday, August 31. One analyst has rated the stock with a sales rating, eleven have granted a withholding grade, nineteen have granted a purchase rating and one has assigned a strong purchase rating to the stock. Currently, the stock has an average "Buy" rating and a consensus target price of $ 85.22.

ILLEGAL ACTIVITY NOTICE: "The Associated Banc Corp holds a position of $ 5.13 million in Gilead Sciences, Inc. (GILD)" according to The Ledger Gazette. and is the exclusive property of The Ledger Gazette. If you are viewing this piece in another domain, it was illegally copied and republished in violation of the United States and international copyright and trademark law. The correct version of this piece can be accessed at https://ledgergazette.com/2017/12/07/associated-banc-corp-has-5-13-million-stake-in-gilead-sciences-inc-gild . html

Gilead Sciences Profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and markets drugs in areas of unmet medical need. The Company's portfolio of products and the research portfolio includes treatments for the Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome (HIV / AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular diseases.

  Institutional Property by Neighborhood for Gilead Sciences (NASDAQ: GILD)

Get news and ratings from Gilead Sciences Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and companies related to the FREE Daily Bulletin of MarketBeat.com.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *